Profil
Mark P de Souza was the founder of NFlection Therapeutics, Inc. (founded in 2014) where he served as the Executive Chairman from 2014 to 2022.
He is also the founder of NF2 Therapeutics, Inc., Chromaderm, Inc., FIBRX Derm, Inc., and SonALAsense, Inc. Dr. de Souza's current job(s) include being the Chief Executive Officer & Director at SeylanMED LLC, the Chief Executive Officer at SeylanMED, Inc., and a Director at Phoenicis Therapeutics, Inc.Dr. de Souza's former job includes being the Executive Chairman at Wings Therapeutics, Inc.
Postes actifs de Mark de Souza
| Sociétés | Poste | Début |
|---|---|---|
FIBRX Derm, Inc.
 FIBRX Derm, Inc. Pharmaceuticals: MajorHealth Technology FIBRX Derm, Inc. develops anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa. The company was founded by Mark de Souza, James W. Fordyce and Erkki Ruoslahti and is headquartered in Berkeley, CA. | Fondateur | - |
SeylanMED LLC
 SeylanMED LLC Miscellaneous Commercial ServicesCommercial Services SeylanMED LLC operates as a private biopharmaceutical company that develops a targeted therapy for Seborrheic Keratosis. The company as founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA. | Directeur Général | - |
Chromaderm, Inc.
 Chromaderm, Inc. BiotechnologyHealth Technology Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA. | Directeur Général | - |
SonALAsense, Inc.
 SonALAsense, Inc. BiotechnologyHealth Technology SonALAsense, Inc. provides ALA Sonodynamic Therapy for the treatment of Glioblastoma Multiforme. The company was founded by Stuart Marcus and is headquartered in Berkeley, CA. | Fondateur | - |
SeylanMED, Inc.
 SeylanMED, Inc. BiotechnologyHealth Technology SeylanMED, Inc. engages in the development of topical akt inhibitor as a treatment for seborrheic keratosis. The company was founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA. | Directeur Général | - |
Phoenicis Therapeutics, Inc.
 Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark de Souza
| Sociétés | Poste | Fin |
|---|---|---|
NFlection Therapeutics, Inc.
 NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Fondateur | 01/06/2022 |
NF2 Therapeutics, Inc.
 NF2 Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services NF2 Therapeutics, Inc. develops therapies. The American company was founded by Michael Wootton, Mark P de Souza, Scott Plotkin. Michael Wootton has been the CEO since incorporation. | Fondateur | - |
Wings Therapeutics, Inc.
 Wings Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA. | Président | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Chromaderm, Inc.
Chromaderm, Inc. BiotechnologyHealth Technology Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA. | Health Technology |
NFlection Therapeutics, Inc.
NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Health Technology |
FIBRX Derm, Inc.
FIBRX Derm, Inc. Pharmaceuticals: MajorHealth Technology FIBRX Derm, Inc. develops anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa. The company was founded by Mark de Souza, James W. Fordyce and Erkki Ruoslahti and is headquartered in Berkeley, CA. | Health Technology |
Wings Therapeutics, Inc.
Wings Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA. | Health Technology |
SeylanMED LLC
SeylanMED LLC Miscellaneous Commercial ServicesCommercial Services SeylanMED LLC operates as a private biopharmaceutical company that develops a targeted therapy for Seborrheic Keratosis. The company as founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA. | Commercial Services |
SonALAsense, Inc.
SonALAsense, Inc. BiotechnologyHealth Technology SonALAsense, Inc. provides ALA Sonodynamic Therapy for the treatment of Glioblastoma Multiforme. The company was founded by Stuart Marcus and is headquartered in Berkeley, CA. | Health Technology |
SeylanMED, Inc.
SeylanMED, Inc. BiotechnologyHealth Technology SeylanMED, Inc. engages in the development of topical akt inhibitor as a treatment for seborrheic keratosis. The company was founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA. | Health Technology |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Health Technology |
NF2 Therapeutics, Inc.
NF2 Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services NF2 Therapeutics, Inc. develops therapies. The American company was founded by Michael Wootton, Mark P de Souza, Scott Plotkin. Michael Wootton has been the CEO since incorporation. | Commercial Services |
